GLP-1 Analog for Treatment of GLP-1 Related Diseases
Summary
USPTO published patent application US20260098071A1 for a novel human GLP-1 analog invented by Tao Sun. The disclosed analog demonstrates improved efficacy compared to natural GLP-1 sequence in treating obesity, type 2 diabetes mellitus, fatty liver, and mood disorders including anxiety and depression. The application was filed on December 4, 2024, under application number 18968327.
What changed
USPTO published patent application US20260098071A1 disclosing a novel human glucagon-like peptide-1 (GLP-1) analog. The analog has a modified sequence relative to natural GLP-1 and demonstrates improved therapeutic effects across multiple GLP-1 related diseases including obesity, type 2 diabetes mellitus, fatty liver, and mood disorders such as anxiety and depression. The application claims priority to filing date December 4, 2024.
For pharmaceutical companies and healthcare providers developing GLP-1 based therapies, this patent publication establishes a prior art date and signals active development in the GLP-1 analog space. Competitors should assess freedom-to-operate and monitor prosecution of related claims covering GLP-1 modifications, pharmaceutical compositions, and methods of treatment.
What to do next
- Monitor patent prosecution status for potential license opportunities
- Review freedom-to-operate landscape for GLP-1 therapeutics
- Evaluate competitive landscape for GLP-1 related disease treatments
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
GLP-1 Analog and Use Thereof in Treatment of GLP-1 Related Diseases
Application US20260098071A1 Kind: A1 Apr 09, 2026
Inventors
Tao Sun
Abstract
The present disclosure relates to a novel human glucagon-like peptide-1 (GLP-1) analog. Compared with the natural sequence of GLP-1, the GLP-1 analog has a remarkable effect in improving GLP-1-related diseases such as obesity, type 2 diabetes mellitus (T2DM), and fatty liver (FL), as well as mood disorders such as anxiety and depression.
CPC Classifications
C07K 14/575 A61P 3/04 A61P 3/10 A61P 25/22 A61P 25/24 A61K 38/00
Filing Date
2024-12-04
Application No.
18968327
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.